Introduction
Natural killer (NK) cells are large granular cells that belong to the innate immunity system and to the family of innate lymphoid cells (ILC) [1] . Their principal function is to kill virus-infected and tumoral cells [2] . The activation and function of NK cells are regulated by several membrane receptors, including killer immunoglobulin-like receptors (KIR), CD94/NKG2 lectin-like receptors and the immunoglobulin-like transcript receptors (ILT) [3] . These molecules are designated commonly as NK cell receptors (NKR), and they can have activating or inhibitory functions. The CD94/NKGA heterodimer is an inhibitory receptor, while CD94/NKG2C and NKG2D homodimer are activating receptors [4] . Natural cytotoxicity receptors (NCR) NKp46 (CD335), NKp30 (CD337) and NKp44 (CD336) also regulate the activation of NK cells [5] .
Immunoglobulin-like transcript 2 (ILT2), CD85j or leucocyte immunoglobulin-like receptor B1 (LILRB1), is detected in monocytes, B cells, NK and T cell subsets, and functions as an inhibitory receptor [6] .
Although the major function of NK cells is to kill infected and tumoral cells, it is now accepted that they display characteristics of adaptive immune response, such as antigen-specific memory [7] . Also, NK cells are able to express major histocompatibility complex class II (MHC-II) proteins [8] . Interleukin (IL)-2-activated NK cells express OX40L (CD252) and CD86 upon NKG2D crosslinking, and can induce T cell proliferation [9] .
Dendritic cells (DCs) are professional antigen-presenting cells, whose main functions are to engulf and process antigens and to present them to the T cells in order to induce an immune response. NK cells can influence the adaptive immune system through the interaction with DCs [10] . It has been shown that NK cells induce the maturation of DCs in vitro. Subsequently, DCs are capable of stimulating proliferation of naive CD4
1 T cells and enhancing the cytotoxic activity of NK cells [11] . Furthermore, it has been reported that NK cells can induce the production of interferon (IFN)-a by plasmacytoid DCs stimulated with RNAcontaining immune complexes [12] .
Conversely, NK cells are able to negatively regulate the adaptive immune system. It has been reported that autologous immature dendritic cells (iDCs) are susceptible to NK cell-mediated lysis through the activating NKR, NKp30 [13] . However, the exact mechanism involved in the NKp30-mediated lysis of DC is not well understood. It has been reported that NKp30 recognizes the molecule B7-H6, which is expressed by tumoral cells and by monocytes and neutrophils after ligation of Toll-like receptor (TLR)-4 [14] . The killing of immature DCs guarantees that only iDCs responding to the infectious stimuli can participate in processing antigens and undergo maturation [15] . Mature DCs (mDCs) are resistant to NK-mediated-lysis, probably by the up-regulation of MHC-I molecules [16] . The lysis of dendritic cells might act as quality control by eliminating non-immunogenic iDCs, hence allowing the total activation of the adaptive immune system. However, NK cells not only inhibit adaptive immune response through killing iDCs; it has also been reported that NK cells can prevent T cell function [17] . NK cells can kill autologous activated CD4 1 T cells efficiently, but not resting CD4 1 T cells [18] .
The lysis of activated T cells represents another way in which NK cells regulate the immune response by killing autoreactive CD4 1 T cells and avoiding an autoimmune response. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a wide clinical spectrum, which includes arthritis, cutaneous, neurological and renal manifestations. It affects mainly women between puberty and menopause. In SLE, numerous alterations in immune system has been well described, such as autoantibodies produced by B cells, formation of immune complexes, increase in the production of IFN-a and self-reactive T cells [19, 20] , but little it is known about the role of NK cells in this autoimmune disease. It has been reported that NK cells are significantly diminished in SLE patients compared with healthy volunteers, and that these cells show an enhanced capacity to secrete IFN-g while displaying reduced cytotoxicity [21] . In SLE patients with recent diagnosis, an increased proportion of NKp46 Moreover, a subpopulation of NK cells that expresses MHC-II and CD11c, expressed normally in DCs, was found in a TLR-7 transgenic murine model of lupus (TLR7tg, which contains approximately 10 copies of the endogenous Tlr7 gene). This NK cell population could present antigen efficiently, and could induce autoimmune disease [24, 25] .
Little is known about the immunoregulatory function of NK cells in SLE. Therefore, the aim of this study was to assess the capacity of NK cells to modulate DC function in SLE patients and healthy volunteers, as well as to assess the expression of NK receptors and other molecules reported in lupus-like murine models.
Materials and methods

Subjects
Sixty patients with a diagnosis of SLE were recruited from the department of Rheumatology of the Hospital Dr Ignacio Morones Prieto and from the department of Immunology and Rheumatology of the Instituto Nacional de Ciencias M edicas y Nutrici on Salvador Zubir an. SLE diagnosis was made according to the criteria of the American College of Rheumatology [26] . The mean age of patients was 35Á81 6 13Á23 years. The disease activity score was evaluated according to the SLE disease activity index (SLE-DAI) [27] . Fifty-five healthy volunteers with similar age and same sex as the SLE patients were included as controls (mean age 5 34Á65 6 12Á85 years). All clinical characteristics are summarized in Tables 1 and 2 . In all cases, an informed written consent was obtained, and the local Ethics Committees (Ethics and Research Committee of the Hospital Central Dr Ignacio Morones Prieto and Instituto Nacional de Ciencias M edicas y Nutrici on Salvador Zubir an) approved this study. This work was carried out in accordance with The Code of Ethics of the World Medical 
Antibodies
The following monoclonal anti-human antibodies were used: anti-human CD3 labelled with peridinin chlorophyll (PerCP), anti-human NKp46-phycoerythrin (PE), antihuman NKG2D-PE, anti-human CD107a [lysosomal-associated membrane protein 1 (LAMP-1)] coupled to PE/cyanin 7 (Cy7), anti-human CD11c-PerCP/Cy5 and anti-human human leucocyte antigen D-related (HLA-DR) coupled to allophycocyanin (APC)/Cy7 (BioLegend, San Diego, CA), anti-human CD56 labelled with APC, anti-human ILT2-PE, anti-human CD80-fluorescein isothiocyanate (FITC), antihuman CD86 coupled to PE and anti-human CD134 (OX40)-PE, anti-HLA-DR-PE (eBioscience, San Diego, CA, USA), anti-human CD161-PE (BD Biosciences, San Jos e, CA, USA), anti-human CD159a/NKG2A labelled with phycoerythrin [magnetic affinity cell sorting (MACS); Miltenyi Biotec, Bergisch Gladbach, Germany] and anti-human NKG2C PE-conjugated anti-human NKp30-PE (R&D Systems, Minneapolis, MN, USA). For functional assays the following antibodies were employed: low endotoxin, azide-free (LEAF) purified anti-human NKp30, clone P30-15 and antihuman NKG2D, clone 1D11 (BioLegend).
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMC) were incubated with Fc-blocking antibody (Human TruStain FcX; BioLegend) and stained with specific conjugated monoclonal antibodies to CD3, CD56, CD161, ILT2, NKG2A, NKG2C, NKG2D, NKp46, NKp30, CD86, HLA-DR, CD134 and CD80. To identify a specific subset of NK cells, PBMC were stained with anti-CD3-PerCP, CD56-APC, CD11-PerCP-Cy5.5, HLA-DR-APC-Cy7 and NKp46-PE. Cells were then washed, resuspended in phosphate-buffered saline (PBS) and analysed by multi-parametric flow cytometry. The cells were acquired using the fluorescence activated cell sorter (FACS) Diva Software (BD Biosciences) in a FACSAria II cytometer (BD Biosciences). In order to set gates we used the fluorescence minus one (FMO) strategy. All data were analysed with FlowJo version 10.1 software (TreeStar, Inc., Ashland, OR, USA). 
Cell isolation
In-vitro DC generation
For the in-vitro generation of monocyte derivated DCs (moDC), purified monocytes were plated at a final concentration of 1 3 10 6 monocytes/ml in RPMI-1640 (31) culture medium (GIBCO, Grand Island, NY, USA) supplemented with 15% of FBS (GIBCO), 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO), non-essential amino acids and sodium pyruvate (Sigma Chemical Co., St Louis, MO, USA). Monocytes were cultured in the presence of recombinant human recombinant human granulocyte-macrophage colony-stimulating hormone (rhGM-CSF) (50 ng/ml) and recombinant human IL-4 (15 ng/ml) for 6 and 8 days. At day 6 a fraction of immature DCs (iDCs) was harvested for co-culture with NK cells. Another fraction of iDCs was cultured for 24 additional hours with lipopolysaccharide (LPS) (100 ng/ ml) in order to induce maturation. Cells were harvested at day 8, washed, labelled and analysed for expression of the indicated maturation markers. Culture medium and cytokines were replaced every 2 days.
Carboxyfluorescein diacetate succinimidyl ester (CFSE)-based cytotoxicity assay
Autologous iDCs or mDCs were harvested and washed with PBS. Cells were loaded with 5 mM of CFSE (Molecular Probes, Eugene, OR, USA) and incubated for 10 min at 378C. NK cells were thawed before use and cultured overnight in RPMI supplemented with 10% FBS, penicillin (100 U/ml), streptomycin (100 mg/ml) and glutamine (2 mM). Human recombinant IL-2 (R&D Systems, Inc., Minneapolis, MN, USA) was added for NK cell activation at a final concentration of 50 ng/ml. CFSE-labelled autologous DCs were used as target cells. Co-culture of NK : iDCs or NK : mDCs was performed at different ratios 
Analysis of NKR function
In order to evaluate the role of NKG2D and NKp30 receptors in NK cell cytotoxic function against DCs, NK cells were incubated for 30 min on ice with the following functional degree antibodies, anti-NKG2D (5 lg/ml) and/or anti-NKp30 (3 lg/ml), in three different conditions: anti-NKG2D, anti-NKp30 or anti-NKG2D plus anti-NKp30. After incubation, NK cells were washed with PBS and coculture with previously CFSE-loaded iDCs. In brief, NK/ iDCs were co-cultured for 24 h at different ratios [NK : DC (1 : 5, 1 : 1, 5 : 1)] in the presence of anti-CD107a-PE-Cy7 antibody. Cells were then harvested and analysed by flow cytometry.
Cytokine production assay
For supernatants from NK cells, DC co-cultures were collected and stored at 2808C. Cytokine levels were quantified using the cytokine bead array (CBA) human T helper type 1 (Th1)/Th2 Cytokine Kit II (BD Biosciences), according to the manufacturer's instructions, and then analysed in a FACS Canto II (BD Biosciences).
Statistical analysis
Data were analysed with the GraphPad Prism version 5.01 software. Flow cytometry data were evaluated by using the Mann-Whitney U-test. When indicated, the KruskallWallis test was also performed. Post-hoc analysis was made using Dunnet's post-test. The analysis of correlations between variables was based on Spearman's rank test. P < 0Á05 was considered statistically significant.
Results
Phenotype of circulating NK cells from SLE patients
First, we assessed the levels of circulating NK cells and NKR from SLE patients and controls. We evaluated 29 patients and controls. Four patients were without treatment at the time of the study. Twenty-five patients were receiving immunosuppressive therapy and median of SLE-DAI activity was 5Á7. The gating tree is shown in Fig. 1a . NK cells were defined as CD3 -CD56 1 cells. As shown in cells compared with healthy controls (median 5 5Á68 versus 9Á14%, respectively, P 5 0Á04). We evaluated the expression of inhibitory and activating receptors in NK cells and observed that although the levels of NK cells positive for the activating receptors NKG2C, NKG2D, NKp30 (Fig. 1c) and NKp46 (data not shown) were similar in SLE patients and controls, the percentages of NK cells positive for the inhibitory receptor ILT2 were significantly higher in SLE patients compared to the control group (median 5 38Á28 versus 22Á70% respectively, P 5 0Á002) (Fig. 1d) . However, we did not observe differences in the levels of NK cells expressing NKG2A; furthermore, the surface expression of all the receptors studied, measured as mean fluorescence intensity (MFI), showed similar results in both groups (data not shown).
NK cells expressing CD86, CD134 and HLA-DR are increased in SLE patients
It has been reported that NK cells express co-stimulatory molecules CD80 and CD86, as well as MHC-II molecules [28] . We decided to evaluate the expression of these important activating molecules, as well as the expression of CD134, as this molecule has an important role in the interaction of NK : DC. The levels of CD80
1 NK cells were similar in SLE patients and controls (Fig. 2a) . Interestingly, the percentages of NK cells positive for CD86 and CD134 (P 5 0Á02) were significantly higher in SLE patients compared to controls (P < 0Á05 in both cases) (Fig. 2b,c) . Importantly, the percentage of NK cells positive for HLA-DR was significantly higher in SLE patients. Notably, we as the median and the interquartile range. *P < 0Á05; **P < 0Á005; ***P < 0Á0001. found SLE patients with more than 90% of NK cells positive for this MHC class II molecule (Fig. 2d) . When we analysed MFI (data not shown) we found no difference between both groups studied, suggesting that it is the number of positive cells, but not the density of molecules on one cell surface, that differs in SLE patients. We assessed the possible impact of immunosuppressive therapy in the expression of these molecules and we found no significant difference between patients receiving treatment and those who were not (P > 0Á05). (Fig. 3a) . We assumed that the percentage of DC survival correlated inversely with NK cell-mediated cytotoxicity. We also assessed the degranulation of NK cells by measuring CD107a expression (Fig. 3b) . When we analysed immature DC survival after 24 h of culture we found that the percentage of DC survival was lower in SLE samples at the three different ratios of NK : DC (Fig. 3c, left panel) . As expected, NK-mediated lysis of DCs was observed at a higher NK cell proportion only in healthy controls (NK : DC, 5 : 1) (Fig. 3c) . We observed that the percentage of mature DC survival is diminished significantly in SLE patients compared with controls at 8 (data not shown) and 24 h in all ratios, including in the absence of NK cells, indicating that mature DCs in SLE have less survival ability independently of NK cell function (Fig. 3c, right panel) . In this regard, when surface expression of CD107a was evaluated at 8 h of coculture, we found that NK cells from SLE patients showed diminished CD107a expression compared to controls. This was observed in co-cultures with iDCs at a ratio of 1 : 1 effector : target cells (Fig. 3d, right panel) and in cocultures with mDC at 1 : 5 and 5 : 1 ratios (Fig. 3d, left  panel) . However, at 24 h of co-culture the surface expression of CD107a was similar in SLE patients compared with controls in all ratios (data not shown). Our results show that NK cells from SLE patients display an impaired cytotoxic function, whereas their DCs have less survival capacity. Controls are displayed in grey bars and SLE patients in black bars. *P < 0Á05; **P < 0Á005; ***P < 0Á0001.
Regulatory function of NK cells in SLE
NK cells regulate adaptive immune responses by lysing DCs and this function is altered in SLE
To analyse the possible involvement of the inflammatory milieu related to SLE in this phenomenon, we decided to analyse a cohort of patients in remission of SLE and compare them with a group of patients with a SLEDAI activity index > 4 (Fig. 4) . As described previously, NK cells from healthy controls induce immature DC lysis at a higher NK cell ratio. Immature and mature DCs from healthy controls were resistant to lysis at 8 h (data not shown), but at 24 h we observed a slight but significant increase in DC lysis at higher NK cell proportions (5 : 1) (Fig. 4a) . Interestingly, NK : DC co-cultures from patients in remission had a similar behaviour to those from healthy controls (Fig. 4a,c) . It is important to point out that in healthy controls and in most of the remission patients we did not observe spontaneous lysis of DCs. Conversely, DCs from patients with active SLE showed reduced survival in the absence of NK cells; this was true for immature and mature DC (Fig.4b,d) . Furthermore, the reduction in immature and mature DC survival was promoted by co-culture with NK cells, suggesting that in this case NK cells mediated DC lysis (Fig. 4a,c) .
In all cases, the possible association of our results with the immunosuppressive therapy was evaluated. Patients were divided according to their therapy: (i) prednisone plus anti-malarial, (ii) methotrexate plus prednisone, (iii) methotrexate, prednisone and a combination of azathioprine or mycophenolate mofetil (MMF), and (iv) no treatment. We found no difference between groups in any case (P > 0Á05, Kruskal-Wallis test and Dunn's multiple comparison test).
Role of NKp30 and NKG2D in the immunoregulatory function of NK cells
To evaluate the role of NKp30 and NKG2D in NK cell function, we performed NK/DC co-cultures at different ratios, as mentioned previously, and in the presence or absence of the following antibodies -anti-NKp30, anti-NKG2D or anti-NKp30 plus anti-NKG2D -and evaluated CD107a expression in NK cells (Fig. 5) . In healthy controls, we could not observe any effect by blocking these activating receptors. Interestingly, we found that the preincubation of NK cells with anti-NKp30 promotes a slight increase in degranulation of NK cells in SLE patients when compared with the non-blocking condition (Fig. 5a-c) ; this effect could also be observed when NK cells were incubated in the presence of anti-NKp30 plus anti-NKG2D at a 1 : 5 NK : DC ratio (Fig. 5a) . With regard to the NKG2D receptor, its inhibition showed no effect on NK cell degranulation (Fig. 5a-c) .
Cytokine levels on co-cultures of NK : DCs
We observed that DCs from SLE patients presented increased levels of lysis in co-cultures with NK cells, even when NK degranulation was diminished. Therefore, we decided to evaluate cytokine levels in the supernatants of these co-cultures. We found similar levels of inflammatory cytokines in all the conditions analysed. IFN-g and tumour necrosis factor (TNF)-a concentrations were similar in those co-cultures from SLE patients and healthy controls (Fig. 6a,b) . The same was found for IL-10 ( Fig. 6c) . Interestingly, we detected significantly lower levels of IL-6 (P 5 0Á02) in supernatants from SLE cultures at a ratio of NK : DC 1 : 1 (Fig. 6d) .
Identification of a new subset of CD11c 1 HLA-DR
1
NK cells increased in SLE patients
New subsets of NK cells, referred to as NK : DC or atypical NK cells [24, 25, 29] , have been described. These NK cell subsets are characterized by the co-expression of NK cell markers, including NK1.1 and some DCs markers, including CD11c, MHC-II and co-stimulatory molecules. Nevertheless, these new NK cell subsets are not well characterized in humans. We decided to assess whether this population of atypical NK cells could also be identified in SLE patients. We evaluated 10 SLE patients. All patients were under immunosuppressive therapy. The mean SLEDAI activity index was 3Á3. We chose the lymphocyte gate based on size and granularity characteristics, and then identified CD3 -CD56 1 cells. We analysed NKp46 expression to guarantee NK cell lineage and the percentages of CD11c 1 HLA-DR 1 cells from the CD3 -CD56 1 NKp46 1 subpopulation (Fig. 7a) . Surprisingly, approximately 10% of NK cells display the atypical phenotype in healthy controls, and this was significantly higher in SLE patients (mean 5 25%, P 5 0Á007) (Fig. 7b,c) . Interestingly, in the SLE group the percentage of atypical NK cells correlated negatively with the SLEDAI activity index (Fig. 7d) .
Discussion
NK cells have been described as playing a pivotal role in the innate immune responses. Currently, it is widely accepted that they have regulatory functions, which is clear from studies in animal models of autoimmune diseases. An impairment of NK cell-mediated regulatory function has been described in multiple sclerosis [30] . In this study, we analysed for the first time, to our knowledge, the regulatory functions of NK cells in SLE. We found reduced levels of NK cells in peripheral blood from SLE patients compared to healthy controls, as it has been described previously [31, 32] . This reduction in the numbers of circulating NK cells may be explained by the recruitment of these cells into sites of inflammation, as it has been reported for other inflammatory diseases such as rheumatoid arthritis, where an increase of CD56 bright NK cells has been observed in synovial fluid of inflamed joints. However, we cannot exclude the possibility of recruitment to lymph nodes or to increased levels of NK cell apoptosis [33, 34] . Circulating NK cells expressing the inhibitory receptor ILT2 were increased in SLE patients. ILT2 is an inhibitory receptor that inhibits NK cell cytolytic function [35] . We have reported previously an impaired function of ILT2 in peripheral blood mononuclear cells from SLE patients [36] . However, the function of this receptor in NK cells from SLE donors has not been yet explored. Although the expression of NKR assessed in this study was similar in both our groups, it was extremely interesting that SLE patients displayed a high variation of percentages of NK cells expressing NKG2C. This may reflect the complex scenario of analysing the NK cell phenotype. It has been reported that human cytomegalovirus (HCMV) infection is associated significantly with an increased expression of some cell membrane receptors expressed by NK lymphocytes. In particular, HCMV-seropositive apparently healthy adult individuals exhibit a significantly enhanced proportion of NK and T lymphocytes that express the CD94/NKG2C NK receptor, which is accompanied by increased levels of ILT2 expression [37] . It has been reported that the risk of acquiring HCMV infection through life is high, and the presence of anti-HCMV antibodies in serum from apparently healthy individuals can reach 100% in developing countries [38] . The possible impact of HCMV infection in our results was not fully evaluated. However, we were not able to detect differences in the expression of NKG2C in NK cells from SLE patients compared to controls, suggesting that HCMV infection may not have a relevant influence in our results. HLA-DR is a MHC-II molecule, which expression is restricted to antigen-presenting cells. However, it has been described that in human NK cells the expression of MHC-II can be induced by stimulation with IL-2 [39] . Remarkably, we found that SLE patients have significantly increased levels of NK cells expressing HLA-DR molecule, which suggests that NK cells in lupus displaying an activating phenotype may be due to the inflammatory milieu found on this autoimmune disease [40] . In support of this, we also found that the co-stimulatory molecules CD86 and CD134 are also increased in NK cells from SLE individuals. It has been reported previously that the expression of CD86 in NK cells confers them with an activating phenotype and enhances cytotoxicity against tumours [41, 42] . In this context, the higher proportions of CD86
1 NK cells we detected in SLE patients could be implicated importantly in the deregulation of the immune response observed in this pathology.
CD134 (OX40) is a molecule expressed in T cells, interacts with OX40L (CD252), expressed on DCs and regulates T cell survival [43] . Moreover, it is known that this molecule is expressed on NK cells after activation [9] , but its function in NK cells remains unknown. We decided to evaluate the expression of CD134, as this molecule could intervene in the interaction between NK and DC. We found an increased frequency of CD134 1 NK cells in SLE patients. An increased percentage of circulating OX40L 1 myeloid DCs has been reported in blood from active SLE patients, and the OX40-OX40L axis may contribute to the pathogenesis of SLE [44] . Our results provide new evidence in this regard; the expression of CD134 in NK cells may allow them to interact with OX40L 1 myeloid DCs, prompting adaptive immune responses. Together, NK cells in SLE may participate in the initiation of adaptive immune responses, in this manner promoting the production of autoantibodies.
We observed that NK cells from SLE patients kill immature DCs more efficiently than controls. We hypothesized that in SLE the over-killing of immature dendritic cells could be a two-edged sword. On one hand, NK cells may kill immature DCs that have captured and processed selfantigens, thus limiting the number of iDCs that may undergo maturation and present autoantigens to autoreactive T cells. On the other hand, however, the killing of immature dendritic cells may contribute to the loss of peripheral tolerance, which is a clue to the pathogenesis of SLE. We also found that mature DCs from SLE patients are more susceptible to lysis mediated by NK cells. In this regard, it has been reported that IL-10 reverses the susceptibility of mature DCs from NK cell-mediated deletion. Although we did not evaluate IL-10 plasma levels in SLE patients, it is well known that this cytokine plays a role in SLE. The higher levels of IL-10 observed in SLE patients may explain the susceptibility of mature DCs from NK cellmediated lysis in this group [45] . It is possible that the killing of mature DCs represents a mechanism that counteracts the activation of autoreactive T cells and may be involved in achieving remission of the disease [46] .
It is well known that activating NKR regulate NK cell activity. Surprisingly, blocking NKp30 and NKG2D receptors did not affect the lysis mediated by NK cells in both SLE patients and controls. This observation, together with the fact that we could not detect differences in the expression of CD107a in our different experimental conditions, indicates that another contact-dependent or soluble factor may be involved in the lysis of immature DCs. In this regard, it is feasible that the Fas-FasL or TNF-related apoptosis-inducing ligand (TRAIL)-TRAIL-R interaction are involved in this phenomenon [47, 48] .
In mice, the expression of MHC-II molecules by NK cells identifies a specific population of NK cells with a DC phenotype [29] . This population of atypical NK cells is increased in an experimental TLR-7 transgenic murine model of lupus. Atypical NK cells have been shown to participate as antigen-presenting cells with lytic functions [24, 25] . In humans, a similar NK population has been described in multiple sclerosis, where the levels of CD11c 
CD11c
1 expanded in SLE patients. Furthermore, NK cells from SLE patients display an aberrant phenotype together with an impaired regulatory function, which supports its important role in the pathogenesis of this disease, and indicates them as a possible target for future therapies.
